Is CLLS or SDGR more profitable?

Schrodinger has a net margin of -40.61% compared to Cellectis' net margin of -89.51%. Schrodinger's return on equity of -30.85% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -89.51% -80.66% -20.51% Schrodinger -40.61% -30.85% -15.32%

Cellectis (CLLS) Competitors

$2.90 -0.09 (-3.01%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$2.93 +0.03 (+1.03%)

As of 07/13/2026 04:04 PM Eastern

Compare

CLLS vs. CAPR, AVLN, WVE, SDGR, and PURR

Should you buy Cellectis stock or one of its competitors? MarketBeat compares Cellectis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectis include Capricor Therapeutics (CAPR), Avalyn Pharma (AVLN), WAVE Life Sciences (WVE), Schrodinger (SDGR), and Hyperliquid Strategies (PURR). These companies are all part of the "pharmaceutical products" industry.

How does Cellectis compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Cellectis has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	53.59	-$105.04M	-$2.32	N/A
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A

Capricor Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Cellectis has a beta of 2.88, meaning that its stock price is 188% more volatile than the broader market.

In the previous week, Capricor Therapeutics had 1 more articles in the media than Cellectis. MarketBeat recorded 2 mentions for Capricor Therapeutics and 1 mentions for Cellectis. Cellectis' average media sentiment score of 1.87 beat Capricor Therapeutics' score of 0.63 indicating that Cellectis is being referred to more favorably in the news media.

Company	Overall Sentiment
Capricor Therapeutics	Positive
Cellectis	Very Positive

Capricor Therapeutics currently has a consensus target price of $53.67, suggesting a potential upside of 160.39%. Cellectis has a consensus target price of $7.00, suggesting a potential upside of 141.38%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Capricor Therapeutics is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Capricor Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Capricor Therapeutics' return on equity of -59.27% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Cellectis	-89.51%	-80.66%	-20.51%

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cellectis beats Capricor Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cellectis compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Cellectis (NASDAQ:CLLS) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Avalyn Pharma has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A

Avalyn Pharma currently has a consensus target price of $59.00, indicating a potential upside of 111.93%. Cellectis has a consensus target price of $7.00, indicating a potential upside of 141.38%. Given Cellectis' higher possible upside, analysts clearly believe Cellectis is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Avalyn Pharma had 2 more articles in the media than Cellectis. MarketBeat recorded 3 mentions for Avalyn Pharma and 1 mentions for Cellectis. Cellectis' average media sentiment score of 1.87 beat Avalyn Pharma's score of 0.62 indicating that Cellectis is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalyn Pharma	Positive
Cellectis	Very Positive

63.9% of Cellectis shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Avalyn Pharma has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Avalyn Pharma's return on equity of 0.00% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Cellectis	-89.51%	-80.66%	-20.51%

Summary

Avalyn Pharma and Cellectis tied by winning 7 of the 14 factors compared between the two stocks.

How does Cellectis compare to WAVE Life Sciences?

Cellectis (NASDAQ:CLLS) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, WAVE Life Sciences had 2 more articles in the media than Cellectis. MarketBeat recorded 3 mentions for WAVE Life Sciences and 1 mentions for Cellectis. Cellectis' average media sentiment score of 1.87 beat WAVE Life Sciences' score of 0.63 indicating that Cellectis is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectis	Very Positive
WAVE Life Sciences	Positive

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cellectis has a net margin of -89.51% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Cellectis presently has a consensus target price of $7.00, suggesting a potential upside of 141.38%. WAVE Life Sciences has a consensus target price of $26.41, suggesting a potential upside of 343.90%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Cellectis has a beta of 2.88, meaning that its share price is 188% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.29, meaning that its share price is 229% less volatile than the broader market.

Cellectis has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A
WAVE Life Sciences	$42.73M	26.79	-$204.38M	-$1.06	N/A

Summary

Cellectis beats WAVE Life Sciences on 9 of the 17 factors compared between the two stocks.

How does Cellectis compare to Schrodinger?

Cellectis (NASDAQ:CLLS) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Schrodinger had 1 more articles in the media than Cellectis. MarketBeat recorded 2 mentions for Schrodinger and 1 mentions for Cellectis. Cellectis' average media sentiment score of 1.87 beat Schrodinger's score of 0.73 indicating that Cellectis is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectis	Very Positive
Schrodinger	Positive

Cellectis has a beta of 2.88, meaning that its share price is 188% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

Schrodinger has a net margin of -40.61% compared to Cellectis' net margin of -89.51%. Schrodinger's return on equity of -30.85% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Schrodinger	-40.61%	-30.85%	-15.32%

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cellectis currently has a consensus price target of $7.00, indicating a potential upside of 141.38%. Schrodinger has a consensus price target of $20.25, indicating a potential upside of 23.40%. Given Cellectis' stronger consensus rating and higher probable upside, research analysts clearly believe Cellectis is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cellectis has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A
Schrodinger	$255.87M	4.73	-$103.26M	-$1.41	N/A

Summary

Cellectis beats Schrodinger on 9 of the 16 factors compared between the two stocks.

How does Cellectis compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Cellectis (NASDAQ:CLLS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Hyperliquid Strategies has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,034.26	-$16.01M	-$7.37	N/A
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A

In the previous week, Hyperliquid Strategies had 4 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 1 mentions for Cellectis. Cellectis' average media sentiment score of 1.87 beat Hyperliquid Strategies' score of 0.65 indicating that Cellectis is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperliquid Strategies	Positive
Cellectis	Very Positive

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Hyperliquid Strategies has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.88, indicating that its stock price is 188% more volatile than the broader market.

Hyperliquid Strategies has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Hyperliquid Strategies' return on equity of -56.04% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Cellectis	-89.51%	-80.66%	-20.51%

Hyperliquid Strategies currently has a consensus target price of $12.72, indicating a potential upside of 77.61%. Cellectis has a consensus target price of $7.00, indicating a potential upside of 141.38%. Given Cellectis' stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Cellectis beats Hyperliquid Strategies on 11 of the 17 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLLS vs. The Competition

Export

Metric	Cellectis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$300.02M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-4.33	20.85	27.11	24.26
Price / Sales	3.66	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	3.82	8.49	10.75	6.29
Net Income	-$67.59M	$23.83M	$3.58B	$330.66M
7 Day Performance	-9.94%	-3.56%	-2.06%	-1.32%
1 Month Performance	-6.15%	6.31%	3.32%	-0.64%
1 Year Performance	34.88%	48.30%	26.36%	19.08%

Cellectis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLLS Cellectis	3.3316 of 5 stars	$2.90 -3.0%	$7.00 +141.4%	+82.4%	$300.02M	$79.59M	N/A	290	Positive News
CAPR Capricor Therapeutics	2.5473 of 5 stars	$22.28 -0.7%	$53.67 +140.9%	+169.8%	$1.29B	$22.27M	N/A	101
AVLN Avalyn Pharma	4.1148 of 5 stars	$28.49 +3.0%	$59.00 +107.1%	N/A	$1.26B	N/A	N/A	51
WVE WAVE Life Sciences	2.758 of 5 stars	$6.44 +1.8%	$26.41 +310.4%	-22.7%	$1.24B	$42.73M	N/A	240
SDGR Schrodinger	2.0093 of 5 stars	$16.68 -1.9%	$20.25 +21.4%	-21.9%	$1.23B	$255.87M	N/A	790

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLLS) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectis (CLLS) Competitors

CLLS vs. CAPR, AVLN, WVE, SDGR, and PURR

How does Cellectis compare to Capricor Therapeutics?

Summary

How does Cellectis compare to Avalyn Pharma?

Summary

How does Cellectis compare to WAVE Life Sciences?

Summary

How does Cellectis compare to Schrodinger?

Summary

How does Cellectis compare to Hyperliquid Strategies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectis (CLLS) Competitors

CLLS vs. CAPR, AVLN, WVE, SDGR, and PURR

How does Cellectis compare to Capricor Therapeutics?

Which has preferable earnings and valuation, CAPR or CLLS?

Which has more volatility and risk, CAPR or CLLS?

Does the media prefer CAPR or CLLS?

Do analysts prefer CAPR or CLLS?

Is CAPR or CLLS more profitable?

Do insiders and institutionals hold more shares of CAPR or CLLS?

Summary

How does Cellectis compare to Avalyn Pharma?

Which has better earnings and valuation, AVLN or CLLS?

Do analysts prefer AVLN or CLLS?

Does the media favor AVLN or CLLS?

Do insiders & institutionals believe in AVLN or CLLS?

Is AVLN or CLLS more profitable?

Summary

How does Cellectis compare to WAVE Life Sciences?

Does the media refer more to CLLS or WVE?

Do insiders & institutionals hold more shares of CLLS or WVE?

Is CLLS or WVE more profitable?

Do analysts recommend CLLS or WVE?

Which has more risk and volatility, CLLS or WVE?

Which has better valuation & earnings, CLLS or WVE?

Summary

How does Cellectis compare to Schrodinger?

Does the media refer more to CLLS or SDGR?

Which has more risk and volatility, CLLS or SDGR?

Is CLLS or SDGR more profitable?

Do insiders & institutionals have more ownership in CLLS or SDGR?

Do analysts recommend CLLS or SDGR?

Which has preferable earnings and valuation, CLLS or SDGR?

Summary

How does Cellectis compare to Hyperliquid Strategies?

Which has preferable earnings and valuation, PURR or CLLS?

Does the media prefer PURR or CLLS?

Do institutionals and insiders have more ownership in PURR or CLLS?

Which has more risk and volatility, PURR or CLLS?

Is PURR or CLLS more profitable?

Do analysts prefer PURR or CLLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools